ROLAPITANT | ROLAPITANT : Antagonist of TACR1
RATINGS:
Cellular Use: (0 reviews)

In Model Organisms: (0 reviews)
Control Compounds
Vendors

Probe Summary

Targets Biochemical/Biophysical Potency Cellular Potency
TACR1
  • Ki:0.66 nM
Antagonist
up to 100 nM

Selectivity

In Vitro Selectivity Assessment
Potency Assay Off-Target:
Selectivity within target family: >1000-fold for the human NK1 receptor compared to the human NK2 an ...

Potency
Cellular
In Vitro

TACR1

Mode of Action: Antagonist

Structure-Activity-Relationship data available? No

DOI Reference: 10.1016/j.pbb.2012.03.021

In Vivo Validations

Gerbils
Dose: 0.3 mg/kg, 1.0 mg/Kg IV, o.3 mg/Kg PO
Route of delivery: Intravenous, Oral
Target engagement assay: Intravenous rolapitant (0.3 and 1 mg/kg) dose-dependently blocked the foot tapping induced byGR-73632 with complete blockade observed at 1 mg/kg, iv.

DOI Reference: 10.1016/j.pbb.2012.03.021

Chemical Information

Molecular Formula C25H26F6N2O2
InChI InChI=1S/C25H26F6N2O2/c1-16(17-11-19(24(26,27)28)13-20(12-17)25(29,30)31)35-15-23(18-5-3-2-4-6-18)10-9-22(14-32-23)8-7-21(34)33-22/h2-6,11-13,16,32H,7-10,14-15H2,1H3,(H,33,34)/t16-,22-,23-/m1/s1
Molecular weight 500.19 Da
AlogP 0.0
HBond acceptors 4
HBond donors 2
Atoms 61

References

Cross References

canSARChEMBL

Expert Reviews


No SERP comments found for ROLAPITANT

Probe ROLAPITANT is in the process of SERP review.

Please continue to check back for new reviews and commentary.